Evolution of the Average Target: Axsome Therapeutics, Inc.

Evolution of the Target Price: Axsome Therapeutics, Inc.

Changes in Analyst Recommendations: Axsome Therapeutics, Inc.

ff69.47uufZA0VFZ5olsH3w2aPSKNIVYRMFGc9A3SrucrWck.iIuZDtdmLAke-jxDjD23SXjdewNDRQDKgn6x5bV_EIu1wcIr8lEdORfKGg~73de531b8ea0b9f565a35368ab1165e2
05-27 Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says MT
05-05 B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating MT
05-05 Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating MT
05-05 RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating MT
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
05-04 Deutsche Bank Adjusts Axsome Therapeutics PT to $281 From $245, Maintains Buy Rating MT
04-29 Mizuho Keeps Price Target on Axsome Therapeutics to $228, Maintains Outperform Rating MT
04-29 Mizuho Adjusts Price Target on Axsome Therapeutics to $228 From $230, Maintains Outperform Rating MT
04-28 Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating MT
04-21 Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says MT
04-10 Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says MT
04-10 UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating MT
04-07 RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating MT
03-13 Axsome Still Offers 'Compelling' Core Story, RBC Says MT
02-24 UBS Adjusts Axsome Therapeutics Price Target to $251 From $248, Maintains Buy Rating MT
02-24 RBC Raises Price Target on Axsome Therapeutics to $222 From $219, Keeps Outperform Rating MT
02-19 Mizuho Adjusts Price Target on Axsome Therapeutics to $230 From $217, Maintains Outperform Rating MT
02-02 Axsome Therapeutics AXS-05 Alzheimer's Launch Could Drive Upside, RBC Says MT
01-21 RBC Raises Price Target on Axsome Therapeutics to $219 From $212, Keeps Outperform Rating MT
01-08 Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 MT
01-08 RBC Raises Price Target on Axsome Therapeutics to $212 From $198, Keeps Outperform Rating MT
01-06 UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating MT
01-02 Deutsche Bank Raises Price Target on Axsome Therapeutics to $223 From $186, Keeps Buy Rating MT
12-31 Mizuho Lifts Price Target on Axsome Therapeutics to $217 From $202, Keeps Outperform Rating MT
12-12 Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+11.55%
+36.05%
+16.19%
+61.86%
+22.26%
+10.29%
-26.78%
+6.37%
+56.1%
+6.04%
Average +19.99%
Weighted average by Cap. +23.56%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
247.85USD
Average target price
276.47USD
Spread / Average Target
+11.55%
High Price Target
380.00USD
Spread / Highest target
+53.32%
Low Price Target
200.00USD
Spread / Lowest Target
-19.31%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

B. Riley
Mizuho Securities
RBC Capital Markets
Deutsche Bank Securities
UBS
Morgan Stanley
Oppenheimer
Truist Securities
BofA Securities
Baird
Citigroup
HC Wainwright
Piper Sandler
Guggenheim
SMBC Nikko
BTIG
SVB Securities LLC
Loop Capital
Jefferies & Co.
Cantor Fitzgerald
Cowen
Berenberg Bank
SVB Leerink
Ladenburg Thalmann
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
247.85USD
Average target price
276.47USD
Spread / Average Target
+11.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock
  4. Consensus Axsome Therapeutics, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!